Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
Cryoglobulinemia | 11 | 2019 | 144 | 3.78 | Why? |
Behcet Syndrome | 7 | 2018 | 136 | 3.30 | Why? |
Vasculitis | 10 | 2019 | 691 | 2.47 | Why? |
Uveitis | 10 | 2020 | 233 | 2.31 | Why? |
Hepatitis C, Chronic | 7 | 2019 | 973 | 1.74 | Why? |
Hepatitis C | 8 | 2018 | 1514 | 1.48 | Why? |
Takayasu Arteritis | 5 | 2018 | 83 | 1.33 | Why? |
Systemic Vasculitis | 2 | 2017 | 74 | 1.28 | Why? |
Hepacivirus | 7 | 2019 | 1509 | 1.12 | Why? |
Sarcoidosis | 5 | 2021 | 271 | 1.09 | Why? |
Imidazoles | 3 | 2018 | 631 | 1.01 | Why? |
Sofosbuvir | 2 | 2017 | 518 | 0.93 | Why? |
Scleritis | 3 | 2020 | 25 | 0.92 | Why? |
Infliximab | 4 | 2018 | 502 | 0.91 | Why? |
Tuberculosis, Ocular | 2 | 2018 | 14 | 0.89 | Why? |
Aortitis | 2 | 2017 | 39 | 0.86 | Why? |
Diagnostic Techniques, Ophthalmological | 6 | 2018 | 136 | 0.83 | Why? |
Adalimumab | 3 | 2018 | 389 | 0.81 | Why? |
Sustained Virologic Response | 3 | 2018 | 378 | 0.80 | Why? |
Rheumatoid Factor | 1 | 2019 | 67 | 0.78 | Why? |
Anti-Glomerular Basement Membrane Disease | 1 | 2019 | 31 | 0.78 | Why? |
Toll-Like Receptor 9 | 1 | 2019 | 72 | 0.78 | Why? |
Immunosuppressive Agents | 15 | 2020 | 6331 | 0.76 | Why? |
Mechanistic Target of Rapamycin Complex 1 | 1 | 2018 | 78 | 0.71 | Why? |
Optic Nerve Diseases | 1 | 2018 | 40 | 0.71 | Why? |
Sclera | 1 | 2017 | 31 | 0.69 | Why? |
T-Lymphocytes, Regulatory | 3 | 2018 | 698 | 0.69 | Why? |
Hepatitis Viruses | 1 | 2017 | 38 | 0.67 | Why? |
Myocytes, Smooth Muscle | 1 | 2018 | 127 | 0.67 | Why? |
Cryoglobulins | 1 | 2017 | 51 | 0.67 | Why? |
Simeprevir | 1 | 2017 | 62 | 0.66 | Why? |
Giant Cell Arteritis | 4 | 2020 | 137 | 0.66 | Why? |
Th1 Cells | 2 | 2019 | 1228 | 0.61 | Why? |
Immune Tolerance | 3 | 2018 | 608 | 0.61 | Why? |
Interferon-gamma Release Tests | 2 | 2017 | 253 | 0.60 | Why? |
TOR Serine-Threonine Kinases | 1 | 2018 | 385 | 0.60 | Why? |
Ustekinumab | 1 | 2017 | 216 | 0.58 | Why? |
B-Lymphocyte Subsets | 1 | 2017 | 372 | 0.58 | Why? |
Drugs, Investigational | 1 | 2017 | 198 | 0.55 | Why? |
Antiviral Agents | 12 | 2020 | 41703 | 0.53 | Why? |
Autoantibodies | 4 | 2019 | 2094 | 0.52 | Why? |
Eye Diseases | 3 | 2020 | 1150 | 0.49 | Why? |
B-Lymphocytes | 4 | 2019 | 4418 | 0.45 | Why? |
Opportunistic Infections | 1 | 2017 | 602 | 0.44 | Why? |
Receptors, Complement 3d | 3 | 2019 | 60 | 0.42 | Why? |
Ribavirin | 2 | 2017 | 1182 | 0.42 | Why? |
Sjogren's Syndrome | 3 | 2018 | 284 | 0.41 | Why? |
T-Lymphocyte Subsets | 1 | 2017 | 1387 | 0.38 | Why? |
Antirheumatic Agents | 3 | 2018 | 3023 | 0.38 | Why? |
Interleukin 1 Receptor Antagonist Protein | 1 | 2017 | 1165 | 0.37 | Why? |
Tumor Necrosis Factor-alpha | 5 | 2018 | 2483 | 0.36 | Why? |
Endothelial Cells | 1 | 2018 | 2048 | 0.34 | Why? |
Metalloproteases | 1 | 2007 | 34 | 0.34 | Why? |
Recurrence | 6 | 2020 | 3675 | 0.33 | Why? |
Immunologic Memory | 1 | 2019 | 3362 | 0.33 | Why? |
Interleukin-2 | 2 | 2018 | 443 | 0.32 | Why? |
Remission Induction | 3 | 2018 | 950 | 0.30 | Why? |
Aorta | 2 | 2019 | 355 | 0.30 | Why? |
Polyneuropathies | 1 | 2007 | 157 | 0.29 | Why? |
Valine | 2 | 2017 | 359 | 0.29 | Why? |
Drug Design | 1 | 2017 | 2627 | 0.28 | Why? |
Antibodies, Antiphospholipid | 2 | 2020 | 519 | 0.27 | Why? |
Immunity, Cellular | 1 | 2017 | 3614 | 0.26 | Why? |
Aortic Diseases | 2 | 2018 | 362 | 0.26 | Why? |
Biological Therapy | 2 | 2018 | 456 | 0.26 | Why? |
Treatment Outcome | 15 | 2018 | 51732 | 0.25 | Why? |
Carbamates | 2 | 2017 | 485 | 0.25 | Why? |
Follow-Up Studies | 10 | 2019 | 17020 | 0.25 | Why? |
Middle Aged | 44 | 2021 | 270681 | 0.25 | Why? |
Pyrrolidines | 2 | 2017 | 558 | 0.25 | Why? |
Tuberculin Test | 3 | 2018 | 141 | 0.24 | Why? |
Autoimmune Diseases | 5 | 2018 | 1996 | 0.24 | Why? |
Th17 Cells | 2 | 2018 | 657 | 0.24 | Why? |
Thrombosis | 3 | 2020 | 7504 | 0.23 | Why? |
Interleukins | 2 | 2018 | 762 | 0.23 | Why? |
Internal Medicine | 2 | 2018 | 557 | 0.23 | Why? |
Retrospective Studies | 26 | 2021 | 105322 | 0.23 | Why? |
Humans | 79 | 2021 | 930598 | 0.23 | Why? |
Female | 47 | 2021 | 380317 | 0.22 | Why? |
France | 12 | 2020 | 12074 | 0.22 | Why? |
Practice Guidelines as Topic | 4 | 2018 | 15421 | 0.22 | Why? |
Antibodies, Monoclonal | 2 | 2018 | 8041 | 0.22 | Why? |
Rheumatic Diseases | 1 | 2017 | 2675 | 0.22 | Why? |
Male | 43 | 2021 | 367725 | 0.21 | Why? |
Adrenal Cortex Hormones | 4 | 2019 | 6537 | 0.21 | Why? |
Lip | 1 | 2020 | 61 | 0.21 | Why? |
Chemokines | 1 | 2007 | 1095 | 0.21 | Why? |
Paris | 3 | 2021 | 1287 | 0.21 | Why? |
Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2019 | 58 | 0.20 | Why? |
Orbital Pseudotumor | 1 | 2018 | 5 | 0.20 | Why? |
Apolipoprotein A-I | 1 | 2020 | 148 | 0.20 | Why? |
Polymyalgia Rheumatica | 1 | 2019 | 64 | 0.19 | Why? |
Adult | 35 | 2021 | 244371 | 0.19 | Why? |
Cyclophosphamide | 2 | 2017 | 387 | 0.19 | Why? |
Orbit | 1 | 2018 | 51 | 0.18 | Why? |
Diagnosis, Differential | 6 | 2018 | 7220 | 0.18 | Why? |
Budd-Chiari Syndrome | 1 | 2018 | 31 | 0.18 | Why? |
Lymphoma, Primary Effusion | 1 | 2017 | 11 | 0.18 | Why? |
Mastocytosis | 1 | 2019 | 80 | 0.18 | Why? |
Familial Mediterranean Fever | 1 | 2019 | 88 | 0.18 | Why? |
Tumor Necrosis Factors | 1 | 2017 | 28 | 0.18 | Why? |
Tuberculosis, Cardiovascular | 1 | 2017 | 4 | 0.18 | Why? |
Prospective Studies | 11 | 2021 | 43301 | 0.17 | Why? |
Receptors, CXCR5 | 1 | 2017 | 35 | 0.17 | Why? |
Intestinal Neoplasms | 1 | 2017 | 42 | 0.17 | Why? |
Vena Cava, Inferior | 1 | 2018 | 103 | 0.17 | Why? |
Quinoxalines | 1 | 2018 | 95 | 0.17 | Why? |
Neuritis | 1 | 2019 | 109 | 0.17 | Why? |
Visual Acuity | 3 | 2018 | 790 | 0.17 | Why? |
Aneurysm, Infected | 1 | 2017 | 36 | 0.17 | Why? |
Immunologic Factors | 3 | 2018 | 4206 | 0.17 | Why? |
Expert Testimony | 2 | 2018 | 658 | 0.17 | Why? |
Benzofurans | 1 | 2018 | 91 | 0.17 | Why? |
Paraproteinemias | 1 | 2017 | 61 | 0.16 | Why? |
Primary Cell Culture | 1 | 2018 | 501 | 0.16 | Why? |
Visual Fields | 1 | 2018 | 123 | 0.16 | Why? |
Granuloma | 1 | 2017 | 88 | 0.16 | Why? |
Lymphoproliferative Disorders | 1 | 2018 | 110 | 0.16 | Why? |
Antimetabolites, Antineoplastic | 1 | 2017 | 99 | 0.16 | Why? |
Inflammation | 5 | 2020 | 13255 | 0.16 | Why? |
Macular Edema | 1 | 2018 | 139 | 0.16 | Why? |
Sarcoma, Kaposi | 1 | 2017 | 97 | 0.16 | Why? |
Sirolimus | 1 | 2018 | 240 | 0.16 | Why? |
Health Planning Guidelines | 1 | 2017 | 133 | 0.16 | Why? |
Azathioprine | 1 | 2017 | 161 | 0.16 | Why? |
Oral Ulcer | 1 | 2017 | 70 | 0.16 | Why? |
Contraindications, Drug | 1 | 2017 | 281 | 0.15 | Why? |
Still's Disease, Adult-Onset | 1 | 2017 | 100 | 0.15 | Why? |
Drug Hypersensitivity Syndrome | 1 | 2017 | 74 | 0.15 | Why? |
Adipose Tissue | 1 | 2021 | 612 | 0.15 | Why? |
Aged | 25 | 2021 | 215776 | 0.15 | Why? |
Capillary Leak Syndrome | 1 | 2017 | 119 | 0.15 | Why? |
Oxidative Stress | 1 | 2007 | 2050 | 0.15 | Why? |
Aneurysm, False | 1 | 2017 | 88 | 0.15 | Why? |
Plasma Cells | 1 | 2018 | 464 | 0.15 | Why? |
Arthralgia | 1 | 2017 | 173 | 0.15 | Why? |
Pragmatic Clinical Trials as Topic | 1 | 2017 | 350 | 0.15 | Why? |
Urogenital Neoplasms | 1 | 2017 | 177 | 0.14 | Why? |
Glucocorticoids | 4 | 2020 | 4431 | 0.14 | Why? |
Rituximab | 3 | 2017 | 1096 | 0.14 | Why? |
Injections, Subcutaneous | 1 | 2017 | 647 | 0.14 | Why? |
Aortic Aneurysm | 1 | 2017 | 121 | 0.14 | Why? |
Autoimmunity | 2 | 2019 | 841 | 0.14 | Why? |
Phosphorylation | 1 | 2018 | 1060 | 0.14 | Why? |
Case-Control Studies | 3 | 2018 | 17671 | 0.14 | Why? |
Vision Disorders | 1 | 2018 | 260 | 0.14 | Why? |
Prevalence | 8 | 2021 | 25773 | 0.14 | Why? |
Time Factors | 8 | 2018 | 31397 | 0.14 | Why? |
Pulmonary Edema | 1 | 2018 | 430 | 0.13 | Why? |
Drug Therapy, Combination | 3 | 2017 | 7268 | 0.13 | Why? |
Antitubercular Agents | 2 | 2017 | 775 | 0.13 | Why? |
Plasmapheresis | 1 | 2017 | 437 | 0.13 | Why? |
Interleukin-17 | 1 | 2018 | 602 | 0.13 | Why? |
Orbital Diseases | 1 | 2018 | 339 | 0.13 | Why? |
Pericarditis | 1 | 2019 | 417 | 0.13 | Why? |
Patient Transfer | 1 | 2020 | 898 | 0.13 | Why? |
Intracranial Thrombosis | 1 | 2018 | 339 | 0.13 | Why? |
Eye | 1 | 2017 | 374 | 0.12 | Why? |
Biological Products | 2 | 2018 | 2331 | 0.12 | Why? |
Ageusia | 1 | 2020 | 918 | 0.12 | Why? |
CD4 Lymphocyte Count | 1 | 2017 | 1517 | 0.12 | Why? |
Immune System Diseases | 1 | 2017 | 410 | 0.12 | Why? |
Kidney Failure, Chronic | 2 | 2019 | 3222 | 0.12 | Why? |
Central Nervous System Diseases | 1 | 2017 | 410 | 0.12 | Why? |
Arterial Occlusive Diseases | 1 | 2017 | 363 | 0.12 | Why? |
Signal Transduction | 2 | 2019 | 7207 | 0.11 | Why? |
HIV Infections | 1 | 2017 | 11620 | 0.11 | Why? |
Immunoglobulins | 1 | 2017 | 811 | 0.11 | Why? |
Pulmonary Artery | 1 | 2018 | 803 | 0.11 | Why? |
Myalgia | 1 | 2017 | 1015 | 0.11 | Why? |
Cells, Cultured | 2 | 2019 | 5835 | 0.11 | Why? |
Antiphospholipid Syndrome | 1 | 2017 | 533 | 0.11 | Why? |
Cell Proliferation | 1 | 2018 | 1973 | 0.11 | Why? |
Diagnostic Imaging | 1 | 2019 | 1044 | 0.11 | Why? |
Immunoglobulin M | 2 | 2019 | 9091 | 0.10 | Why? |
Prognosis | 8 | 2021 | 32490 | 0.10 | Why? |
Vascular Diseases | 1 | 2018 | 846 | 0.10 | Why? |
Lymphocyte Activation | 1 | 2019 | 2742 | 0.10 | Why? |
Phenotype | 2 | 2019 | 4037 | 0.10 | Why? |
Myocardium | 1 | 2021 | 2323 | 0.10 | Why? |
Blood Platelets | 1 | 2020 | 1704 | 0.10 | Why? |
Lupus Erythematosus, Systemic | 2 | 2017 | 1380 | 0.09 | Why? |
Health Care Costs | 1 | 2017 | 1007 | 0.09 | Why? |
Folliculitis | 1 | 2008 | 12 | 0.09 | Why? |
Dendritic Cells | 1 | 2017 | 1330 | 0.09 | Why? |
Staphylococcal Skin Infections | 1 | 2008 | 32 | 0.09 | Why? |
Young Adult | 13 | 2018 | 93724 | 0.09 | Why? |
Leukocidins | 1 | 2008 | 47 | 0.09 | Why? |
Hospitalization | 6 | 2021 | 54280 | 0.09 | Why? |
Exotoxins | 1 | 2008 | 54 | 0.09 | Why? |
Physicians | 2 | 2018 | 4214 | 0.09 | Why? |
Steroids | 3 | 2020 | 904 | 0.09 | Why? |
Interferon-gamma | 1 | 2018 | 2711 | 0.09 | Why? |
HSP72 Heat-Shock Proteins | 1 | 2007 | 4 | 0.09 | Why? |
Peroneal Nerve | 1 | 2007 | 13 | 0.09 | Why? |
Molecular Targeted Therapy | 1 | 2017 | 1579 | 0.09 | Why? |
Monocytes | 1 | 2020 | 2978 | 0.09 | Why? |
Metallothionein | 1 | 2007 | 20 | 0.09 | Why? |
Polyarteritis Nodosa | 1 | 2007 | 25 | 0.09 | Why? |
Dose-Response Relationship, Drug | 1 | 2017 | 3776 | 0.09 | Why? |
Biomarkers | 4 | 2020 | 23361 | 0.08 | Why? |
Cytokines | 3 | 2020 | 15010 | 0.08 | Why? |
Gene Expression | 1 | 2017 | 3332 | 0.08 | Why? |
Nitric Oxide Synthase Type III | 1 | 2007 | 87 | 0.08 | Why? |
Bacterial Toxins | 1 | 2008 | 185 | 0.08 | Why? |
HSP90 Heat-Shock Proteins | 1 | 2007 | 98 | 0.08 | Why? |
Viral Load | 2 | 2017 | 15850 | 0.08 | Why? |
Diagnostic Tests, Routine | 1 | 2018 | 2643 | 0.08 | Why? |
Anticoagulants | 2 | 2018 | 9563 | 0.08 | Why? |
Transcriptome | 1 | 2019 | 3466 | 0.08 | Why? |
Forecasting | 1 | 2020 | 4492 | 0.08 | Why? |
Antibodies, Monoclonal, Humanized | 2 | 2018 | 9335 | 0.07 | Why? |
Disease Susceptibility | 1 | 2019 | 4002 | 0.07 | Why? |
Ophthalmology | 1 | 2020 | 1840 | 0.07 | Why? |
Gene Expression Regulation | 1 | 2018 | 4020 | 0.07 | Why? |
Pilot Projects | 1 | 2017 | 5182 | 0.07 | Why? |
Immunoglobulins, Intravenous | 1 | 2017 | 2705 | 0.07 | Why? |
Lymphocyte Count | 1 | 2017 | 4758 | 0.07 | Why? |
Health Knowledge, Attitudes, Practice | 2 | 2018 | 8811 | 0.07 | Why? |
Anti-Inflammatory Agents | 3 | 2018 | 6153 | 0.07 | Why? |
Cardiovascular Diseases | 3 | 2019 | 11497 | 0.07 | Why? |
Sex Factors | 2 | 2019 | 11014 | 0.07 | Why? |
Neutrophils | 1 | 2020 | 5476 | 0.07 | Why? |
Skin Neoplasms | 1 | 2017 | 1679 | 0.07 | Why? |
Diabetes Mellitus, Type 1 | 1 | 2018 | 1969 | 0.06 | Why? |
Immunocompromised Host | 1 | 2020 | 5150 | 0.06 | Why? |
Survival Rate | 1 | 2018 | 9206 | 0.06 | Why? |
Logistic Models | 1 | 2018 | 9089 | 0.06 | Why? |
Interleukin-6 | 1 | 2021 | 7522 | 0.06 | Why? |
Prednisone | 2 | 2018 | 652 | 0.06 | Why? |
Symptom Assessment | 1 | 2017 | 4967 | 0.06 | Why? |
Risk Factors | 5 | 2020 | 71621 | 0.06 | Why? |
Aged, 80 and over | 8 | 2021 | 88759 | 0.06 | Why? |
Disease Management | 2 | 2019 | 6841 | 0.06 | Why? |
Venous Thrombosis | 1 | 2018 | 2739 | 0.06 | Why? |
CD4-Positive T-Lymphocytes | 1 | 2017 | 4545 | 0.06 | Why? |
Methicillin-Resistant Staphylococcus aureus | 1 | 2008 | 711 | 0.06 | Why? |
Gene Expression Profiling | 2 | 2017 | 3788 | 0.06 | Why? |
Neoplasms | 2 | 2021 | 17251 | 0.05 | Why? |
Heart Diseases | 1 | 2018 | 3503 | 0.05 | Why? |
Ultrasonography | 1 | 2017 | 4409 | 0.05 | Why? |
Triage | 1 | 2020 | 7151 | 0.05 | Why? |
Tissue Plasminogen Activator | 1 | 2007 | 778 | 0.05 | Why? |
Organ Size | 1 | 2021 | 384 | 0.05 | Why? |
Lung Neoplasms | 1 | 2017 | 3228 | 0.05 | Why? |
Radiography, Thoracic | 1 | 2017 | 5486 | 0.05 | Why? |
Diabetes Mellitus, Type 2 | 1 | 2021 | 6166 | 0.05 | Why? |
Survival Analysis | 3 | 2018 | 7592 | 0.05 | Why? |
Hospital Mortality | 2 | 2021 | 22087 | 0.05 | Why? |
Uveitis, Anterior | 1 | 2020 | 71 | 0.05 | Why? |
Immunity, Innate | 1 | 2017 | 6570 | 0.05 | Why? |
Flow Cytometry | 2 | 2018 | 2393 | 0.05 | Why? |
Severity of Illness Index | 4 | 2021 | 48226 | 0.05 | Why? |
Up-Regulation | 1 | 2007 | 2249 | 0.05 | Why? |
Incidence | 2 | 2018 | 25622 | 0.05 | Why? |
Cross Infection | 1 | 2021 | 8675 | 0.05 | Why? |
Biopsy | 2 | 2018 | 2811 | 0.05 | Why? |
Clinical Trials as Topic | 1 | 2018 | 7330 | 0.05 | Why? |
B7-1 Antigen | 1 | 2017 | 39 | 0.05 | Why? |
Registries | 1 | 2018 | 12327 | 0.05 | Why? |
Constriction, Pathologic | 1 | 2019 | 212 | 0.05 | Why? |
Enzyme-Linked Immunosorbent Assay | 3 | 2018 | 7868 | 0.04 | Why? |
Terbutaline | 1 | 2017 | 35 | 0.04 | Why? |
Intravitreal Injections | 1 | 2020 | 347 | 0.04 | Why? |
Retinal Vasculitis | 1 | 2017 | 33 | 0.04 | Why? |
Theophylline | 1 | 2017 | 39 | 0.04 | Why? |
Aortic Rupture | 1 | 2018 | 64 | 0.04 | Why? |
Aortography | 1 | 2017 | 60 | 0.04 | Why? |
Ophthalmologic Surgical Procedures | 1 | 2020 | 211 | 0.04 | Why? |
Immunoprecipitation | 1 | 2018 | 300 | 0.04 | Why? |
Age of Onset | 1 | 2019 | 557 | 0.04 | Why? |
Intensive Care Units | 2 | 2021 | 29594 | 0.04 | Why? |
Stroke | 1 | 2020 | 8839 | 0.04 | Why? |
Hydroxychloroquine | 1 | 2021 | 12447 | 0.04 | Why? |
Herpesvirus 8, Human | 1 | 2017 | 97 | 0.04 | Why? |
Fluorescent Antibody Technique, Indirect | 1 | 2018 | 393 | 0.04 | Why? |
Mesenteric Ischemia | 1 | 2018 | 128 | 0.04 | Why? |
Immunoglobulin G | 2 | 2018 | 21571 | 0.04 | Why? |
Antibodies, Antinuclear | 1 | 2017 | 234 | 0.04 | Why? |
Microscopy, Electron, Transmission | 1 | 2017 | 605 | 0.04 | Why? |
Receptors, Antigen, B-Cell | 1 | 2018 | 424 | 0.04 | Why? |
Outpatient Clinics, Hospital | 1 | 2020 | 523 | 0.04 | Why? |
Lymphoma, B-Cell | 1 | 2017 | 166 | 0.04 | Why? |
Fluorescein Angiography | 1 | 2018 | 426 | 0.04 | Why? |
Aorta, Thoracic | 1 | 2017 | 271 | 0.04 | Why? |
Fluorescent Antibody Technique | 1 | 2017 | 835 | 0.03 | Why? |
Cigarette Smoking | 1 | 2018 | 337 | 0.03 | Why? |
Medical Records | 1 | 2017 | 513 | 0.03 | Why? |
B7-H1 Antigen | 1 | 2017 | 541 | 0.03 | Why? |
Withholding Treatment | 1 | 2020 | 798 | 0.03 | Why? |
Syndrome | 1 | 2018 | 1310 | 0.03 | Why? |
Ambulatory Care | 2 | 2020 | 4947 | 0.03 | Why? |
Adolescent | 6 | 2018 | 86841 | 0.03 | Why? |
Pneumonia, Viral | 5 | 2020 | 243684 | 0.03 | Why? |
Predictive Value of Tests | 2 | 2019 | 9537 | 0.03 | Why? |
Polymerase Chain Reaction | 2 | 2018 | 6740 | 0.03 | Why? |
Coronavirus Infections | 5 | 2020 | 253789 | 0.03 | Why? |
Healthy Volunteers | 1 | 2018 | 1444 | 0.03 | Why? |
Disease-Free Survival | 1 | 2017 | 1654 | 0.03 | Why? |
Pandemics | 6 | 2021 | 389249 | 0.03 | Why? |
Heart | 1 | 2021 | 1791 | 0.03 | Why? |
Cell Differentiation | 1 | 2017 | 1338 | 0.03 | Why? |
C-Reactive Protein | 2 | 2018 | 7972 | 0.03 | Why? |
Cohort Studies | 3 | 2021 | 36005 | 0.03 | Why? |
Tomography, Optical Coherence | 1 | 2018 | 1008 | 0.03 | Why? |
Administration, Oral | 1 | 2017 | 2340 | 0.02 | Why? |
Phenindione | 1 | 2008 | 5 | 0.02 | Why? |
Interdisciplinary Communication | 1 | 2017 | 1425 | 0.02 | Why? |
Ofloxacin | 1 | 2008 | 23 | 0.02 | Why? |
Immunomodulation | 1 | 2018 | 1472 | 0.02 | Why? |
Betacoronavirus | 4 | 2020 | 204454 | 0.02 | Why? |
Groin | 1 | 2008 | 22 | 0.02 | Why? |
Orthomyxoviridae | 1 | 2017 | 1168 | 0.02 | Why? |
Operating Rooms | 1 | 2020 | 1841 | 0.02 | Why? |
Mycobacterium tuberculosis | 1 | 2018 | 1164 | 0.02 | Why? |
Disease Progression | 2 | 2018 | 13580 | 0.02 | Why? |
Aspirin | 1 | 2017 | 1043 | 0.02 | Why? |
Scrotum | 1 | 2008 | 48 | 0.02 | Why? |
Leg Ulcer | 1 | 2008 | 32 | 0.02 | Why? |
Drug Combinations | 1 | 2018 | 3852 | 0.02 | Why? |
Vascular Surgical Procedures | 1 | 2017 | 882 | 0.02 | Why? |
Stomatitis, Aphthous | 1 | 2008 | 43 | 0.02 | Why? |
Animals | 1 | 2017 | 78931 | 0.02 | Why? |
Kaplan-Meier Estimate | 1 | 2017 | 4260 | 0.02 | Why? |
Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2008 | 170 | 0.02 | Why? |
Medication Adherence | 1 | 2017 | 1270 | 0.02 | Why? |
Single-Cell Analysis | 1 | 2017 | 2450 | 0.02 | Why? |
Heart Transplantation | 1 | 2017 | 1293 | 0.02 | Why? |
Clinical Protocols | 1 | 2018 | 2734 | 0.02 | Why? |
Graft Rejection | 1 | 2017 | 1766 | 0.02 | Why? |
Computed Tomography Angiography | 1 | 2017 | 2153 | 0.02 | Why? |
Chlorhexidine | 1 | 2008 | 176 | 0.02 | Why? |
Kidney Diseases | 1 | 2017 | 1434 | 0.02 | Why? |
Genotype | 1 | 2018 | 4697 | 0.02 | Why? |
Adaptive Immunity | 1 | 2017 | 2585 | 0.02 | Why? |
Necrosis | 1 | 2008 | 532 | 0.02 | Why? |
Emergencies | 1 | 2020 | 4095 | 0.02 | Why? |
Child | 3 | 2020 | 70012 | 0.02 | Why? |
Proportional Hazards Models | 1 | 2017 | 6543 | 0.02 | Why? |
Hemorrhage | 1 | 2017 | 3013 | 0.02 | Why? |
Patient Discharge | 1 | 2020 | 5696 | 0.02 | Why? |
Interferon Type I | 1 | 2017 | 2789 | 0.02 | Why? |
Interferons | 1 | 2017 | 2885 | 0.02 | Why? |
Evidence-Based Medicine | 1 | 2017 | 3228 | 0.02 | Why? |
Psoriasis | 1 | 2017 | 1739 | 0.02 | Why? |
Primary Health Care | 1 | 2020 | 4839 | 0.01 | Why? |
Anti-Infective Agents, Local | 1 | 2008 | 520 | 0.01 | Why? |
Colchicine | 1 | 2008 | 730 | 0.01 | Why? |
Magnetic Resonance Imaging | 1 | 2018 | 6551 | 0.01 | Why? |
Real-Time Polymerase Chain Reaction | 1 | 2020 | 11367 | 0.01 | Why? |
Algorithms | 1 | 2018 | 7346 | 0.01 | Why? |
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.01 | Why? |
Infant, Newborn | 1 | 2020 | 23105 | 0.01 | Why? |
Mass Screening | 1 | 2017 | 8005 | 0.01 | Why? |
Mutation | 1 | 2018 | 12376 | 0.01 | Why? |
Infant | 1 | 2020 | 30274 | 0.01 | Why? |
Anti-Infective Agents | 1 | 2008 | 1766 | 0.01 | Why? |
Child, Preschool | 1 | 2020 | 36283 | 0.01 | Why? |
Community-Acquired Infections | 1 | 2008 | 2328 | 0.01 | Why? |
Risk Assessment | 1 | 2019 | 25439 | 0.01 | Why? |
Tomography, X-Ray Computed | 1 | 2021 | 25144 | 0.01 | Why? |
Comorbidity | 1 | 2018 | 34796 | 0.01 | Why? |
United States | 1 | 2020 | 46150 | 0.01 | Why? |
Cross-Sectional Studies | 1 | 2020 | 53120 | 0.01 | Why? |
Telemedicine | 1 | 2020 | 25032 | 0.01 | Why? |
Anti-Bacterial Agents | 1 | 2008 | 10083 | 0.00 | Why? |